Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Authors: Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo

Source: Future Journal of Pharmaceutical Sciences, Vol 11, Iss 1, Pp 1-12 (2025)

Subject Terms: IDH inhibitors, Enasidenib, Ivosidenib, Olutasidenib, FAERS, Pharmacovigilance, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://doaj.org/toc/2314-7253

Access URL: https://doaj.org/article/7cf8e751a5e442c5afc990ab7cf0cb77

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Authors: Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito

Source: Case Reports in Oncology, Vol 17, Iss 1, Pp 753-762 (2024)

Subject Terms: intrahepatic cholangiocarcinoma, idh1, ivosidenib, sustained clinical response, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/539665; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/6e8323bdf50942259611c4a779b6ca61

Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan

Authors: Kuei-An Chen, Wei-Ming Huang, Eric Yi-Ting Chen, Pei-Kuan Ho, Chen-Han Chueh, Yu-Wen Wen, Ming-Huang Chen, Nai-Jung Chiang, Yi-Wen Tsai

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)

Subject Terms: Ivosidenib, Cost-effectiveness, Advanced intrahepatic cholangiocarcinoma, IDH1 mutations, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/b7dcc5a01daf4e9b80d16cdb8a522158

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

Authors: Alexander Bray, Vaibhav Sahai

Source: Current Oncology, Vol 32, Iss 1, p 44 (2025)

Subject Terms: cholangiocarcinoma, mutant isocitrate dehydrogenase, targeted therapy, ivosidenib, 2-hydroxyglutarate, R2HG, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/32/1/44; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/c6f4adad50324687b797fb39f3992929

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

Authors: Uson Junior PLS, Borad MJ

Source: Cancer Management and Research, Vol Volume 15, Pp 1025-1031 (2023)

Subject Terms: cholangiocarcinoma, biliary tract cancers, ivosidenib, idh1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/clinical-utility-of-ivosidenib-in-the-treatment-of-idh1-mutant-cholang-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

Access URL: https://doaj.org/article/c2ae51a0272a4d14afe7eab5d7c350e2

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis

Authors: Xiu Chen, Hongyun Xing, Xiaolu Xie, Liqiu Kou, Jun Li, Yaling Li

Source: Clinical Epigenetics, Vol 15, Iss 1, Pp 1-12 (2023)

Subject Terms: IDH inhibitors, Ivosidenib, Enasidenib, Acute myeloid leukemia, Meta-analysis, Medicine, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1868-7083

Access URL: https://doaj.org/article/1fb8418815594aef803ff55a77292a12

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

Authors: Mehrdad Zarei, Omid Hajihassani, Jonathan J. Hue, Hallie J. Graor, Alexander W. Loftus, Moeez Rathore, Ali Vaziri-Gohar, John M. Asara, Jordan M. Winter, Luke D. Rothermel

Source: Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)

Subject Terms: Melanoma, IDH1, Ivosidenib, Chemoresistance, Combination therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/81d5fbf1b7e24bb7b6768e02fe81e9ba

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?

Authors: Anjali Bhatt, Kerrington Powell, Vinay Prasad

Source: Translational Oncology, Vol 25, Iss , Pp 101523- (2022)

Subject Terms: AGILE, IDH1-mutant acute myeloid leukemia, Ivosidenib, Azacitidine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1936523322001826; https://doaj.org/toc/1936-5233

Access URL: https://doaj.org/article/65de1306450f494b813c045ecfec8c9e

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence

Authors: Stemer G, Rowe JM, Ofran Y

Source: Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 11, Pp 41-54 (2021)

Subject Terms: mutant idh1, acute myeloid leukemia, ivosidenib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://www.dovepress.com/efficacy-and-safety-profile-of-ivosidenib-in-the-management-of-patient-peer-reviewed-fulltext-article-BLCTT; https://doaj.org/toc/1179-9889

Access URL: https://doaj.org/article/c5b5aacb1fa546c1b7c4b95517c9ddd0

IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia

Authors: Sydney Dunn-Valadez, Srilakshmi Bathini, Carly Elston, Sravanti Rangaraju, Antonio Di Stasi, Sarah Worth, Diana Morlote, Shuko Harada, Pankit Vachhani

Source: Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100560- (2022)

Subject Terms: IDH1, Ivosidenib, Differentiation syndrome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2468294222000508; https://doaj.org/toc/2468-2942

Access URL: https://doaj.org/article/2fa1bcd8c31444e0bc126a135dcd519a

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma

Authors: Anh Huan Vo, Prakash Ambady, David Spencer

Source: Epilepsy & Behavior Reports, Vol 18, Iss , Pp 100526- (2022)

Subject Terms: Epilepsy, Seizure, Oligodendroglioma, Glioma, Ivosidenib, IDH1 mutation, Neurology. Diseases of the nervous system, RC346-429, Neurophysiology and neuropsychology, QP351-495

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S258998642200003X; https://doaj.org/toc/2589-9864

Access URL: https://doaj.org/article/fdaf70cf448c40c2aa651b1b406634c2

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Authors: Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P

Source: Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 9, Pp 19-32 (2019)

Subject Terms: IDH1, isocitrate dehydrogenase 1, acute myeloid leukemia, relapsed/refractory, ivosidenib, FT-2102, venetoclax., Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://www.dovepress.com/idh1-mutated-relapsed-or-refractory-aml-current-challenges-and-future--peer-reviewed-article-BLCTT; https://doaj.org/toc/1179-9889

Access URL: https://doaj.org/article/644517ea4c7d4750a7e0382dca92bc5f

Validated LC-ESI-MS/MS method for the determination of ivosidenib in 10 µL mice plasma: application to a pharmacokinetic study

Authors: Sreekanth Dittakavi, Rakesh Kumar Jat, Sadanand Rangnathrao Mallurwar, Ravi Kumar Jairam, Ramesh Mullangi

Source: ADMET and DMPK, Vol 7, Iss 2, Pp 131-139 (2019)

Subject Terms: Ivosidenib, LC-MS/MS, method validation, mice plasma, pharmacokinetics, bioavailability, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: http://pub.iapchem.org/ojs/index.php/admet/article/view/648; https://doaj.org/toc/1848-7718

Access URL: https://doaj.org/article/b03384e06de14e00937bb38f95cf041f

Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer

Authors: Juan Wu, Ru Chen, Huiqing Shen, Ting Yan, Yu Qian, Yaping Zhang, Zhuoya Huang, Pengzhou Kong, Min Pang, Xinri Zhang

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: ivosidenib, RNA-seq, bioinformatic analysis, ceRNA, non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.626605/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/ca81f9c4634f4a2a8ef38df58cc927dc

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Authors: Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: acute myeloid leukemia, AML, enasidenib, IDH, isocitrate dehydrogenase, ivosidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/a114ff99cd32458eb7e711de3f37c1cd

IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?

Authors: Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi

Source: Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100356- (2021)

Subject Terms: Biliary tract cancer, Cholangiocarcinoma, Ivosidenib, ClarIDHy, Targeted therapies, Intrahepatic cholangiocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S246829422100054X; https://doaj.org/toc/2468-2942

Access URL: https://doaj.org/article/62e25fa71c5041688c1d1e128ed563b5

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study

Authors: Dalissa Tejera, Marina Kushnirsky, Sakir H Gultekin, Min Lu, Lori Steelman, Macarena I de la Fuente

Source: CNS Oncology, Vol 9, Iss 3 (2020)

Subject Terms: glioblastoma, IDH1-mutant, IDH inhibitor, IDH mutation, ivosidenib, low-grade glioma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-0907; https://doaj.org/toc/2045-0915

Access URL: https://doaj.org/article/4d1d7c5a294e4900b9c56edc3f87c21a

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Authors: Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S. Modrek, Dimitris G. Placantonakis

Source: Frontiers in Oncology, Vol 9 (2019)

Subject Terms: acute myeloid leukemia, enasidenib, glioma, IDH, isocitrate dehydrogenase, ivosidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2019.00417/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f275d4fdff3c4d98b3f8c34da88e089d

Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate

Authors: Lorenzo Galluzzi, Guido Kroemer

Source: OncoImmunology, Vol 7, Iss 12 (2018)

Subject Terms: cancer-associated fibroblasts, cytotoxic t lymphocytes, hif-1α, immunosurveillance, immunotherapy, ivosidenib, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2162-402X

Access URL: https://doaj.org/article/cc326378f2304ce1b82231baf3bba641

This result is not displayed to guests.
Login for full access.